These Are 2 of the Smartest Growth Stocks to Invest $5,000 in Today

MercadoLibre reported Q3 net revenue of $7.4 billion, up 40% YoY and marking its 27th consecutive quarter of >30% YoY growth; operating income was $724 million (+30%), adjusted free cash flow $206 million, GMV $16.5 billion (+28%) and TPV $71.2 billion (+41%), highlighting a reinforcing e‑commerce/fintech/logistics flywheel across Latin America. Eli Lilly posted Q3 revenue growth of 54% YoY as tirzepatide became the world’s best‑selling drug in Q3 2025, driving a market cap above $1 trillion; the company is advancing an oral GLP‑1 (orforglipron) expected next year and is investing heavily in manufacturing capacity and AI‑accelerated R&D (including Nvidia‑backed supercomputing) to support continued scale and pipeline expansion.

Analysis

Market structure: MELI’s integrated flywheel (TPV +41%, GMV +28% YoY) amplifies wallet share across commerce, payments, credit and logistics, directly benefiting MercadoLibre, local merchant partners, and regional logistics integrators. Incumbent banks, payment processors, and standalone marketplaces face margin compression as MELI captures take-rates and credit spreads; expect LATAM e‑commerce penetration to rise toward developed-market levels over 3–5 years, pressuring brick-and-mortar revenues. For LLY, tirzepatide/orforglipron dominance shifts pricing power to innovators with scale; payors and rivals (notably NVO) will face negotiation pressure and potential share losses if oral small‑molecule GLP‑1s gain approval and price advantages.

Risk assessment: Tail risks include regulatory pricing intervention in the U.S./EU (drug-pricing caps or formulary exclusions) and LATAM capital/FX shocks that could halve MELI’s USD-reported revenue in a severe BRL/ARS collapse. Short-term (next 30–90 days) risks center on orforglipron approval and quarterly supply updates; medium-term (6–18 months) risks are manufacturing bottlenecks and rising delinquency on Mercado Crédito. Hidden dependencies: MELI’s growth depends on local logistics rollout and merchant credit health; LLY depends on scaled drug manufacturing and favourable payer decisions — both reliant on third-party capex (semiconductors, contract manufacturers).

Trade implications: Direct: initiate 2–3% long MELI (buy on pullback 10–15% or below $X — use current price marker) and 3–5% long LLY, adding after orforglipron approval. Pair: long LLY vs short NVO (1:1 notional) through July 2026 to express conviction in Lilly’s oral small molecule advantage while hedging class-wide pricing pressure. Options: buy LLY Jan 2027 LEAPS calls (or call spreads to fund premium) ahead of a 6–12 month commercial ramp; buy MELI 6–9 month protective puts (10–15% OTM) to insure EM FX/regulatory shocks. Rotate: overweight Healthcare and EM Consumer/Fintech, underweight traditional retail and regional LATAM banks until credit metrics normalize.

Contrarian angles: Consensus underprices regulatory/payer pushback risk — GLP‑1s could face step‑pricing or utilization controls that reduce revenue forecasts by 20–40% vs current bull cases. For MELI, the market may be overestimating near-term monetization of Mercado Crédito; a 200–300bp rise in LATAM unemployment or a 25% FX depreciation could materially reduce TPV growth and force increased provisions. Historical parallels: drug pricing episodes (insulin, hepatitis C) show fast political backlash and pricing pressure after rapid revenue growth; similar dynamics could cap multiples despite fundamental growth. Watch for supply‑side bottlenecks and public policy headlines as immediate mean‑reversion catalysts.

Key Decisions for Investors

• Establish a 2–3% long position in MELI (MercadoLibre) sized to portfolio risk tolerance; add on any >10% pullback or if next-quarter GMV growth remains >25%; hedge with 6–9 month 10–15% OTM puts if BRL/ARS depreciate >10% within 60 days.
• Build a 3–5% core long in LLY (Eli Lilly); initiate with Jan 2027 LEAPS call spread (buy 2027 $400 call, sell $600 call) sized to expected approval timeline, and add another 1–2% on FDA approval of orforglipron or confirmed launch price/reimbursement terms.
• Implement a pair trade: long LLY vs short NVO (equal notional) through July 2026 to express preference for Lilly’s small‑molecule oral advantage; cap downside by buying 6–12 month puts on the short leg if class-wide approvals broaden beyond expectations.
• Reduce exposure to LATAM regional banks and traditional retail by 2–4% of portfolio weight over next 3 months; redeploy into fintech-enabled EM plays (e.g., MELI) while monitoring delinquency rates and unemployment — trim further if delinquency rises >150bps quarter-on-quarter.
• Monitor 30–90 day catalysts: (1) FDA decision timelines for orforglipron, (2) MELI quarterly report for TPV/GMV vs consensus and credit-loss provisions; if orforglipron approval is delayed or MELI credit provisions widen >50bps, cut positions by 25% within one week.